1. Home
  2. HSDT vs ALBT Comparison

HSDT vs ALBT Comparison

Compare HSDT & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSDT
  • ALBT
  • Stock Information
  • Founded
  • HSDT N/A
  • ALBT 2014
  • Country
  • HSDT United States
  • ALBT United States
  • Employees
  • HSDT N/A
  • ALBT N/A
  • Industry
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ALBT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HSDT Health Care
  • ALBT Health Care
  • Exchange
  • HSDT Nasdaq
  • ALBT Nasdaq
  • Market Cap
  • HSDT 6.4M
  • ALBT 7.4M
  • IPO Year
  • HSDT N/A
  • ALBT N/A
  • Fundamental
  • Price
  • HSDT $22.75
  • ALBT $2.61
  • Analyst Decision
  • HSDT Hold
  • ALBT
  • Analyst Count
  • HSDT 1
  • ALBT 0
  • Target Price
  • HSDT N/A
  • ALBT N/A
  • AVG Volume (30 Days)
  • HSDT 1.2M
  • ALBT 78.8K
  • Earning Date
  • HSDT 11-11-2025
  • ALBT 11-11-2025
  • Dividend Yield
  • HSDT N/A
  • ALBT N/A
  • EPS Growth
  • HSDT N/A
  • ALBT N/A
  • EPS
  • HSDT N/A
  • ALBT N/A
  • Revenue
  • HSDT $295,000.00
  • ALBT $1,159,091.00
  • Revenue This Year
  • HSDT N/A
  • ALBT N/A
  • Revenue Next Year
  • HSDT $75.13
  • ALBT N/A
  • P/E Ratio
  • HSDT N/A
  • ALBT N/A
  • Revenue Growth
  • HSDT N/A
  • ALBT N/A
  • 52 Week Low
  • HSDT $5.37
  • ALBT $1.87
  • 52 Week High
  • HSDT $1,200.00
  • ALBT $11.66
  • Technical
  • Relative Strength Index (RSI)
  • HSDT 86.15
  • ALBT 58.03
  • Support Level
  • HSDT $5.78
  • ALBT $2.60
  • Resistance Level
  • HSDT $24.49
  • ALBT $2.90
  • Average True Range (ATR)
  • HSDT 1.62
  • ALBT 0.20
  • MACD
  • HSDT 2.35
  • ALBT 0.06
  • Stochastic Oscillator
  • HSDT 90.70
  • ALBT 68.89

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

About ALBT Avalon GloboCare Corp.

Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Share on Social Networks: